IL15 and colonic neoplasm: Similarly, IL-15-based agonists enhanced the NK cell response to Cetuximab-treated squamous cell carcinoma of head and neck (38) and colon cancer (31) and to Rituximab-treated B cell lymphoma cell lines (36).